Connect with us:   Email This Page  | Print
Learn more about Neuronetics, developer of the NeuroStar TMS Therapy System.
NeuroStar TMS Therapy<sup>®</sup> System

Current Procedural Terminology (CPT)1
Several CPT codes may be used for reporting the various services related to the delivery of TMS therapy. For the NeuroStar TMS Therapy procedure itself, the AMA created Category III CPT codes to report this service. These codes are effective for dates of service on or after January 1, 2007. The Category III codes were released by the AMA and have been available for use effective July 2006. These codes are Category III codes as they were awarded prior to Food and Drug Administration (FDA) approval of NeuroStar TMS Therapy. Under current AMA CPT coding development procedures, Category I codes are not available prior to FDA approval of a new procedure.

Category III CPT codes are temporary codes that allow data collection for emerging technologies, procedures and services. It is important for healthcare providers to report appropriate codes to support accurate tracking of data and provide evidence of utilization of these technologies. Guidance from the AMA indicates that “if a Category III code is available, this code must be reported by healthcare providers in place of an unlisted CPT Category I procedure code.” However, it is recommended you check with specific payers to determine their coding policies. It is always the provider’s responsibility to determine and submit appropriate codes for the services rendered.

Some payers, including Medicare, may not cover or separately reimburse services reported with Category III CPT codes. However, other payers may choose to recognize a Category III CPT code for coverage and payment. The AMA created the following Category III CPT codes for NeuroStar TMS therapy:2

Table 3. NeuroStar TMS Therapy Category III CPT Codes
CPT Code Description
0160T Therapeutic repetitive transcranial magnetic stimulation treatment planning

Pre-treatment determination of optimal magnetic field strength via titration, treatment location determination and stimulation parameter and protocol programming in the therapeutic use of high power, focal magnetic pulses for the direct, noninvasive modulation of cortical neurons.
0161T Therapeutic repetitive transcranial magnetic stimulation treatment delivery and management, per session

Treatment session using high power, focal magnetic pulses for the direct, noninvasive modulation of cortical neurons. Clinical evaluation, safety monitoring and treatment parameter review in the therapeutic use of high power, focal magnetic pulses for the direct noninvasive modulation of cortical neurons.

Code Usage: The AMA created CPT code 0160T to report treatment planning services during the initial patient visit. This includes determining the patient's cortical neuron excitability or motor threshold (MT) value, determining and storing the cortical landmark coordinates corresponding to the location were MT was determined, determining and storing the treatment location coordinates, and selecting and storing treatment parameters for a given treatment protocol. CPT code 0161T was created to report services for each session when treatment is delivered and patient management services are provided. Thus, for the initial visit (day one of TMS Therapy) when a treatment planning session is completed and a treatment delivery session is completed, both 0160T and 0161T should be reported. On subsequent treatment days, when only treatment delivery and management is provided, only 0161T would be reported. Example: If the course of TMS Therapy for a given patient consisted of 26 treatments, 0160T would be reported once and 0161T would be reported 26 times for that patient for this course of therapy. If MT must be re-determined during the course of therapy, code 0160T may be used to identify that service.

Again, the AMA indicates that “if a Category III code is available, this code must be reported by healthcare providers in place of an unlisted CPT Category I procedure code.”2 Nonetheless, if directed by a payer not to use Category III CPT codes 0160T and 0161T or under other circumstances in which a provider performs services not described by a more specific code, the provider may report an unlisted or miscellaneous code such as the following:1

Table 4. Miscellaneous Code
CPT Code Description
90899 Unlisted psychiatric service or procedure

Payers typically manually review unlisted codes to confirm coverage and reimbursement rates for the services provided. To complete this review, the provider may need to submit documentation to the payer describing the services provided, the technology used, and the reasoning behind the treatment (e.g., letter of medical necessity). The AMA notes, “Pertinent information should include an adequate definition or description of the nature, extent, and need for the procedure and the time, effort, and equipment necessary to provide the service. Additional items may include complexity of symptoms, final diagnosis, pertinent physical findings, diagnostic and therapeutic procedures, concurrent problems, and follow-up care.”3 Providers should contact individual payers directly to verify the appropriate code(s) for reporting NeuroStar TMS Therapy and claim documentation requirements.

View the complete Billing Guide

References:
  1. Current Procedural Terminology (CPT® 2008), Professional Edition, American Medical Association, 2007, 449.
  2. Current Procedural Terminology (CPT® 2008), Professional Edition, American Medical Association, 2007.
  3. Current Procedural Terminology (CPT® 2008), Professional Edition, American Medical Association, 2007, xvi
Refer a Patient for Treatment
NeuroStar TMS Therapy may be right for your patients suffering from major depression. Refer them here.
Find a Provider

Become a NeuroStar TMS Therapy Provider
Provide your patients the new way back from depression with NeuroStar TMS Therapy®. Contact us to find out how you can bring NeuroStar into your workplace.
Contact Us


* NeuroStar TMS Therapy® is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from one prior antidepressant medication at or above the minimal effective dose and duration in the current episode. Click here for full prescribing and safety information

Copyright © 2010 Neuronetics. All Rights Reserved Sitemap  | Privacy Policy  | Terms and Conditions  | Glossary
 

You are leaving www.NeuroStarTMS.com, a website of Neuronetics. Links to all outside websites are provided as a resource to our visitors. Neuronetics accepts no responsibility for the content of other websites.

Click here to continue.